DOCSLIB.ORG

Genetic Analysis and Development of a Novel in Vitro Cell Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Disorders of sex development: Genetic analysis and development of a novel in vitro cell model Ingrid May Knarston B.Sc. (Hons.) Submitted in total fulfilment of the requirements of the degree of Doctor of Philosophy October 2018 Department of Paediatrics The University of Melbourne 2 Abstract Disorders/Differences of Sex Development (DSDs) are conditions where the chromosomal, anatomical or gonadal sex is atypical. DSDs are caused by a breakdown in the molecular pathways controlling development of the reproductive organs, such as ovarian/testicular differentiation. These conditions can carry a number of clinical complications such as an increased risk of gonadal cancer, infertility and psychosocial consequences. Importantly, the underlying genetic cause is still unknown in 60% of DSD patients, meaning clinical care is severely compromised. In the first part of this thesis, I studied a cohort of 34 patients with 46,XX (ovo)testicular DSDs. In these individuals, the testicular differentiation pathway is activated in 46,XX genetic females, resulting in the formation of testes or ovotestes. The cohort was studied using massively parallel sequencing and PCR-based approaches. This identified diagnostic findings in nine patients in two known DSD genes (NR5A1 and SOX9), as well as variants in candidate DSD genes (EMX2, FOXL2, LGR5, RXFP2 and WNT9A). In vitro analysis of the NR5A1 variants showed how these variants repress ovarian signalling pathways and factors, sufficient to switch ovarian to testicular development. In vitro and in vivo analyses of three of the candidate genes (EMX2, LGR5 and RXFP2) indicated that they are likely benign variants that don’t contribute to the phenotype. Ongoing studies of two further candidate genes (FOXL2 and WNT9A) will establish their potential role in these DSD phenotypes. In the second part of the thesis, I aimed to develop an improved in vitro model for functionally analysing DSD gene variants. Several recent studies have differentiated human induced pluripotent stem cells (iPSCs) into many different tissues, which can be used as human- and tissue-specific disease models. I developed a protocol to differentiate human iPSCs into testis- like lineages. In this step-wise protocol, cells are directed through the developmental stages that give rise to the embryonic testis. Gene expression profiling has shown that at day 10-12 of iPSC differentiation, cells reach a bipotential gonad-like stage and by day 15 testis-like lineages are induced. This protocol will continue to be optimised, yet already I have shown its promising utility to study novel DSD genes. In summary, genetic analysis of a DSD cohort revealed diagnoses for a number of patients; these findings will likely improve their clinical management. It has also provided information on the most suitable genetic testing approach for 46,XX (ovo)testicular DSDs, a phenotypic group traditionally challenging to diagnose. Further, I showed functional insights into the molecular pathogenesis underlying NR5A1-mediated 46,XX (ovo)testicular DSD. Finally, development of a stem cell-based model of the human testis will help us to establish how novel DSD genes and variants affect human gonad development. ii Declaration This is to certify that: i. This thesis comprises only my original work towards the PhD except where indicated in the Preface, ii. Due acknowledgement has been made in the text to all other material used, iii. This thesis is less than 100,000 words in length, exclusive of tables, maps, bibliographies and appendices Ingrid Knarston: iii Preface Work carried out in collaboration with others as part of this thesis: Chapter 2 DNA and clinical information from all patients used in the studies presented here were collected from national and international collaborating clinicians. MLPA reactions and data analysis was performed in collaboration with Dr. Thomas Ohnesorg (Reproductive Development group, MCRI). Follow up CGH arrays were performed and analysed by Jocelyn van den Bergen (Reproductive Development group, MCRI). Preparation of DNA libraries for MPS was performed by Gorjana Robevska and Jocelyn van den Bergen (Reproductive Development group, MCRI) or at sequencing facilities (Australian Genomics Research Facility and Garvan Institute). The bioinformatic analysis of MPS data was undertaken in collaboration with Dr. Simon Sadedin (MCRI), Katrina Bell (MCRI) and Ben Lundie (Garvan Institute). The in vitro assay testing mutant RXFP2 function was performed by Prof. Ross Bathgate’s group (Florey Institute). The Emx2 and Wnt9a CRISPR mutant mice were generated by Dr. Liang Zhao (Institute of Molecular Bioscience, The University of Queensland) and characterised by Dr. Ella Thomson (Institute of Molecular Bioscience, The University of Queensland) and Dr. Anthony Bird (Hudson Institute for Medical Research, Monash University) respectively. Chapter 3 The in silico modelling of NR5A1 variant proteins and immunofluorescence staining for NR5A1 protein in COS-7 cells was performed by Gorjana Robevska (Reproductive Development group, MCRI). I conducted all other work, comprising 90% of the thesis. iv Publications Ingrid Knarston*, Katie L. Ayers*, Andrew H. Sinclair. Molecular mechanisms associated with 46, XX disorders of sex development. Clinical Science 2016 March 01; 130 (6): 421-432. Corresponding chapter in the thesis: Chapter 1 Contribution to manuscript: I was involved in all aspects of this manuscript. I conceptualised and designed the investigation with KA, conducted the literature analysis and co-wrote the paper with KA. Brittany Croft*, Thomas Ohnesorg*, Josephine Bowles, Katie Ayers, Jacky Hewitt, Jacqueline Tan, Vincent Corbin, Emanuele Pelosi, Jocelyn van den Bergen, Alexander Quinn, Rajini Sreenivisan, Ingrid Knarston, Gorjana Robevska, Dung Vu Chi, John Hutson, Vincent Harley, Peter Koopman and Andrew Sinclair. Human sex reversal is caused by duplication or deletion of core enhancers upstream of SOX9. Nature Communications 2018 Dec 14; 9 (1): 5319. Corresponding chapter in the thesis: Chapter 2 Contribution to manuscript: I was involved in the identification of duplications in the upstream region of SOX9 in two 46,XX DSD patients. Ingrid M. Knarston*, Gorjana Robevska*, Jocelyn A. van den Bergen, Stefanie Eggers, Brittany Croft, Jason Yates, Remko Hersmus, Leendert H.J. Looijenga, Fergus J. Cameron, Klaus Monhike, Katie L. Ayers* and Andrew H. Sinclair*. NR5A1 gene variants repress the ovarian-specific WNT signalling pathway in 46,XX Disorders of Sex Development patients. Human Mutation 2019 Feb; 40 (2): 207-216. Corresponding chapter in thesis: Chapter 3 Contribution to manuscript: I was involved in all aspects of this manuscript. I conceptualised and designed the study with GR and KLA. Experimental work was performed in collaboration with GR and I and co-wrote the paper with GR and KLA. v Acknowledgements I would like to thank each of my supervisors for their support, Dr. Katie Ayers, Prof. Andrew Sinclair, Prof. Melissa Little, Dr. Alex Combes and Dr. Stefanie Eggers. My principal supervisors Katie Ayers and Andrew Sinclair have shaped a PhD project that has been incredibly exciting and challenging. Katie has been so generous with her time in developing my skills as a researcher and providing a constant source of advice and guidance. I am also very grateful for her encouragement to reach outside my comfort zone in so many instances. I am incredibly grateful for the opportunities and guidance that Andrew has provided me, particularly in shaping a PhD project that allowed me to gain experience in both the genomics and iPSC fields. I would like to thank both Melissa Little and Alex Combes for their support in my iPSC project; our discussions have taught me so much about developmental biology and their questions have been really valuable in directing this work. Finally, I would like to thank Stefanie Eggers for sharing her knowledge on DSD and genetic analyses. I would like to thank the entire Reproductive Development group for being such a welcoming and supportive group, Prof. Andrew Sinclair, Katie Griffin, Dr. Katie Ayers, Jocelyn van den Bergen, Gorjana Robevska, Dr. Elena Tucker, Dr. Rajini Sreenivasan, Brittany Croft, Dr. Aurore Bouty, Dr. Thomas Ohnesorg and Chloe Hanna. It has been a privilege to work alongside and learn from such a talented team of people. In particular I would like to thank Gorjana Robevska for helping me with so many aspects of this project and teaching me so many skills, as well as for her constant support and friendship over the years. I would also like to thank Jocelyn van den Bergen for being a constant source of helpful advice and such a big support. I would also like to thank the Kidney group at MCRI for allowing me to learn about iPSC and organoid modelling alongside them. I am very grateful to Irene Ghobrial and Pei Xuan Er for sharing so much of their knowledge and time training me in iPSC and organoid culture. I would also like to thank Dr. Santhosh Kumar for his valuable advice on organoid culture and Dr. Minoru Takasato for his guidance in the early stages of this project. I would like to thank my advisory committee, including Assoc. Prof. Shireen Lamande and Dr. Tiong Tan, for their input on the development of my project. Also at MCRI, I would like to thank vi the Animal house staff for their help with my mouse work and Matt Burton for sharing his knowledge on confocal imaging. Outside of MCRI, I would like to thank all members of the Australian DSD genetics program for the annual retreats that provided a fantastic forum to share ideas and get feedback on my project. Particularly I would like to thank Dr. Liang Zhao, Dr. Ella Thomson and Dr. Anthony Bird for their work on the mutant mouse models. I would also like to thank our collaborators Prof. Ross Bathgate (Florey Institute), Dr. Simon Sadedin (MCRI), Katrina Bell (MCRI) and Ben Lundie (Garvan Institute), for each of their contributions to this work. I would like to thank all of the patients and families who have been involved in this study, as well as all of the collaborating clinicians.
Recommended publications
  • Accepted Version

    Accepted Version

    Article Genetic Control of Gonadal Sex Determination and Development STEVANT, Isabelle, NEF, Serge Abstract Sex determination is the process by which the bipotential gonads develop as either testes or ovaries. With two distinct potential outcomes, the gonadal primordium offers a unique model for the study of cell fate specification and how distinct cell populations diverge from multipotent progenitors. This review focuses on recent advances in our understanding of the genetic programs and epigenetic mechanisms that regulate gonadal sex determination and the regulation of cell fate commitment in the bipotential gonads. We rely primarily on mouse data to illuminate the complex and dynamic genetic programs controlling cell fate decision and sex-specific cell differentiation during gonadal formation and gonadal sex determination. Reference STEVANT, Isabelle, NEF, Serge. Genetic Control of Gonadal Sex Determination and Development. Trends in Genetics, 2019 PMID : 30902461 DOI : 10.1016/j.tig.2019.02.004 Available at: http://archive-ouverte.unige.ch/unige:115790 Disclaimer: layout of this document may differ from the published version. 1 / 1 Trends in Genetics Genetic control of sex determination and gonad development --Manuscript Draft-- Manuscript Number: TIGS-D-18-00173R1 Article Type: Review Keywords: sex determination; ovary; testis; lineage specification; gene expression; epigenetic regulation Corresponding Author: Serge Nef geneva, SWITZERLAND First Author: Isabelle Stévant Order of Authors: Isabelle Stévant Serge Nef Abstract: Sex determination is the process by which the bipotential gonads develop as either testes or ovaries. With two distinct potential outomes, the gonadal primordium offers a unique model for the study of cell fate specification and how distinct cell populations diverge from multipotent progenitors.
  • Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes

    Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes

    International Journal of Molecular Sciences Review Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes Iria Roca, Ana Fernández-Marmiesse, Sofía Gouveia, Marta Segovia and María L. Couce * Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain; [email protected] (I.R.); [email protected] (A.F.-M.); sofi[email protected] (S.G.); [email protected] (M.S.) * Correspondence: [email protected]; Tel.: +34-981-950-102 Received: 3 April 2018; Accepted: 23 May 2018; Published: 27 May 2018 Abstract: The biggest challenge geneticists face when applying next-generation sequencing technology to the diagnosis of rare diseases is determining which rare variants, from the dozens or hundreds detected, are potentially implicated in the patient’s phenotype. Thus, variant prioritization is an essential step in the process of rare disease diagnosis. In addition to conducting the usual in-silico analyses to predict variant pathogenicity (based on nucleotide/amino-acid conservation and the differences between the physicochemical features of the amino-acid change), three important concepts should be borne in mind. The first is the “mutation tolerance” of the genes in which variants are located. This describes the susceptibility of a given gene to any functional mutation and depends on the strength of purifying selection acting against it. The second is the “mutational architecture” of each gene. This describes the type and location of mutations previously identified in the gene, and their association with different phenotypes or degrees of severity.
  • Lamin A/C Cardiomyopathy: Implications for Treatment

    Lamin A/C Cardiomyopathy: Implications for Treatment

    Current Cardiology Reports (2019) 21:160 https://doi.org/10.1007/s11886-019-1224-7 MYOCARDIAL DISEASE (A ABBATE AND G SINAGRA, SECTION EDITORS) Lamin A/C Cardiomyopathy: Implications for Treatment Suet Nee Chen1 & Orfeo Sbaizero1,2 & Matthew R. G. Taylor1 & Luisa Mestroni1 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The purpose of this review is to provide an update on lamin A/C (LMNA)-related cardiomyopathy and discuss the current recommendations and progress in the management of this disease. LMNA-related cardiomyopathy, an inherited autosomal dominant disease, is one of the most common causes of dilated cardiomyopathy and is characterized by steady progression toward heart failure and high risks of arrhythmias and sudden cardiac death. Recent Findings We discuss recent advances in the understanding of the molecular mechanisms of the disease including altered cell biomechanics, which may represent novel therapeutic targets to advance the current management approach, which relies on standard heart failure recommendations. Future therapeutic approaches include repurposed molecularly directed drugs, siRNA- based gene silencing, and genome editing. Summary LMNA-related cardiomyopathy is the focus of active in vitro and in vivo research, which is expected to generate novel biomarkers and identify new therapeutic targets. LMNA-related cardiomyopathy trials are currently underway. Keywords Lamin A/C gene . Laminopathy . Heart failure . Arrhythmias . Mechanotransduction . P53 . CRISPR–Cas9 therapy Introduction functions, including maintaining nuclear structural integrity, regulating gene expression, mechanosensing, and Mutations in the lamin A/C gene (LMNA)causelaminopathies, mechanotransduction through the lamina-associated proteins a heterogeneous group of inherited disorders including muscu- [6–11].
  • WES Gene Package Multiple Congenital Anomalie.Xlsx

    WES Gene Package Multiple Congenital Anomalie.Xlsx

    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway

    Analysis of the Indacaterol-Regulated Transcriptome in Human Airway

    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
  • Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants

    Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants

    Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:40050098 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants A dissertation presented by Seav Huong Ly to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological and Biomedical Sciences Harvard University Cambridge, Massachusetts April 2018 © 2018 Seav Huong Ly All rights reserved. Dissertation Advisor: William C. Hahn Seav Huong Ly Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants Abstract The importance of oncogenic KRAS in human cancers have prompted intense efforts to target KRAS and its effectors. To anticipate the development of resistance to these strategies, we previously performed a genome-scale expression screen to identify genes that bypass KRAS oncogenic dependency. Here we test thirty-seven genes that scored over five standard deviations and find that overexpression of LIM homeobox 9 (LHX9), a transcription factor involved in embryonic development, robustly rescues the suppression of KRAS in vitro and xenograft models. Furthermore, LHX9 substantially decreases cell sensitivity to KRASG12C and MEK1/2 inhibitors in KRAS-dependent cells.
  • The Genetic Mechanism That Links Hutchinson-Gilford Progeria Syndrome to Physiological Aging

    The Genetic Mechanism That Links Hutchinson-Gilford Progeria Syndrome to Physiological Aging

    Department of Biosciences and Nutrition The genetic mechanism that links Hutchinson-Gilford progeria syndrome to physiological aging AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i Hörsalen, plan 4, Novum, Huddinge. Fredagen den 14 februari, 2014, kl 09.15 av Sofía Rodríguez Vásquez B.Sc. Licentiate in Biological Sciences Huvudhandledare: Fakultetsopponent: Docent Maria Eriksson Professor Karima Djabali Karolinska Institutet Technical University Munich Institutionen för Biovetenskaper och Department of Dermatology and Näringslära Institute for Medical Engineering Bihandledare: Betygsnämnd: Professor Karin Dahlman-Wright Docent Rickard Sandberg Karolinska Institutet Karolinska Institutet Institutionen för Biovetenskaper och Institutionen för Cell- och Molekylär Näringslära Biologi Professor Caroline Graff Professor Brun Ulfhake Karolinska Institutet Karolinska Institutet Institutionen för Neurobiologi, Institutionen för Neurovetenskap Vårdvetenskap och Samhälle Professor Jan Dumanski Uppsala Universitet Institutionen för Immunologi, Genetik och Patologi. Enheten för Medicinsk Genetik Stockholm 2014 DEPARTMENT OF BIOSCIENCES AND NUTRITION Karolinska Institutet, Stockholm, Sweden THE GENETIC MECHANISM THAT LINKS HUTCHINSON-GILFORD PROGERIA SYNDROME TO PHYSIOLOGICAL AGING Sofía Rodríguez Vásquez Stockholm 2014 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. © Sofia Rodríguez Vásquez, 2014 ISBN 978-91-7549-372-5 Printed by Printed by 2014 Gårdsvägen 4, 169 70 Solna Dedicated to my beloved parents and life heroes: Benito Rodríguez Rodríguez & Doris Vásquez Silva ABSTRACT Aging is a complex process that is not completely understood. The study of segmental progeroid syndromes such as Hutchinson-Gilford progeria syndrome (HGPS) has allowed us to connect the common genetic mechanisms that occur in normal physiological aging, with the cellular alterations presented by this severe premature aging syndrome.
  • 76F0c47cb71e753c0f29618f48ed

    76F0c47cb71e753c0f29618f48ed

    International Journal of Molecular Sciences Review Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy Lin Jiang, Jialiang Liang , Wei Huang, Zhichao Wu, Christian Paul and Yigang Wang * Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA; [email protected] (L.J.); [email protected] (J.L.); [email protected] (W.H.); [email protected] (Z.W.); [email protected] (C.P.) * Correspondence: [email protected]; Tel.: +1-513-558-5798 Received: 30 September 2020; Accepted: 15 October 2020; Published: 16 October 2020 Abstract: Limited adult cardiac cell proliferation after cardiovascular disease, such as heart failure, hampers regeneration, resulting in a major loss of cardiomyocytes (CMs) at the site of injury. Recent studies in cellular reprogramming approaches have provided the opportunity to improve upon previous techniques used to regenerate damaged heart. Using these approaches, new CMs can be regenerated from differentiation of iPSCs (similar to embryonic stem cells), the direct reprogramming of fibroblasts [induced cardiomyocytes (iCMs)], or induced cardiac progenitors. Although these CMs have been shown to functionally repair infarcted heart, advancements in technology are still in the early stages of development in research laboratories. In this review, reprogramming-based approaches for generating CMs are briefly introduced and reviewed, and the challenges (including low efficiency, functional maturity, and safety issues) that hinder further translation of these approaches into a clinical setting are discussed. The creative and combined optimal methods to address these challenges are also summarized, with optimism that further investigation into tissue engineering, cardiac development signaling, and epigenetic mechanisms will help to establish methods that improve cell-reprogramming approaches for heart regeneration.
  • Arthrogryposis and Congenital Myasthenic Syndrome Precision Panel

    Arthrogryposis and Congenital Myasthenic Syndrome Precision Panel

    Arthrogryposis and Congenital Myasthenic Syndrome Precision Panel Overview Arthrogryposis or arthrogryposis multiplex congenita (AMC) is a group of nonprogressive conditions characterized by multiple joint contractures found throughout the body at birth. It usually appears as a feature of other neuromuscular conditions or part of systemic diseases. Primary cases may present prenatally with decreased fetal movements associated with joint contractures as well as brain abnormalities, decreased muscle bulk and polyhydramnios whereas secondary causes may present with isolated contractures. Congenital Myasthenic Syndromes (CMS) are a clinically and genetically heterogeneous group of disorders characterized by impaired neuromuscular transmission. Clinically they usually present with abnormal fatigability upon exertion, transient weakness of extra-ocular, facial, bulbar, truncal or limb muscles. Severity ranges from mild, phasic weakness, to disabling permanent weakness with respiratory difficulties and ultimately death. The mode of inheritance of these diseases typically follows and autosomal recessive pattern, although dominant forms can be seen. The Igenomix Arthrogryposis and Congenital Myasthenic Syndrome Precision Panel can be as a tool for an accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved, and their high or intermediate penetrance.
  • Supplementary Table 1

    Supplementary Table 1

    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
  • Case Report of Malouf Syndrome Not Associated with LMNA Gene Mutation

    Case Report of Malouf Syndrome Not Associated with LMNA Gene Mutation

    MOJ Clinical & Medical Case Reports Case Report Open Access Case report of malouf syndrome not associated with LMNA gene mutation Abstract Volume 4 Issue 6 - 2016 Malouf syndrome, currently known as dilated cardiomyopathy associated with Tatiyana G Vaikhanskaya,1 Larysa N hypergonadotropic hypogonadism (DCM-НН), is a rare congenital disorder with Sivitskaya,2 Nina G Danilenko,2 Tatsiyana V clinical signs including DCM phenotype, ovary dysgenesis in females or primary 1 2 testicular failure in males, mental retardation, facial dysmorphism, skin lesions, bone Kurushka, Oleg G Davydenko abnormalities and occasionally marfanoid habitus. The disorder can be caused by 1Health Information Technology Department, Republican mutation in the LMNA gene, encoding lamins A and C. In the present manuscript, Scientific and Practical Centre of Cardiology, Belarus we report the sporadic case of a young female with dilated cardiomyopathy, 2Cytoplasmic Inheritance Department, Institute of Genetics hypergonadotropic hypogonadism and primary amenorrhea, cognitive deficiency, and Cytology of the National Academy of Sciences of Belarus, body mass deficit, facial dysmorphism and subclinical hypothyroidism. Radiation Belarus exposure, mumps, diabetes mellitus, autoimmune diseases, and Turner’s syndrome have been ruled out. Specific features of mandibuloacral dysplasia, like bone dysplasia, Correspondence: Tatiyana G Vaikhanskaya, Health Information are absent. The first-degree relatives are healthy. The clinical data suggested a Technology Department, Republican Scientific and Practical laminopathy. Targeted next-generation sequencing was used to search for mutations in Centre of Cardiology, 220036, R Lyuksembourg str 110, Minsk, genes, associated with cardiomyopathy, including LMNA. However, genetic analysis Belarus, Tel +375291307140, Email [email protected] did not confirm the assumption: mutation was not found.
  • Sema4 Cardiac Information Sheet

    Sema4 Cardiac Information Sheet

    CARDIAC NEXT-GENERATION SEQUENCING PANELS Mail: One Gustave L. Levy Place, Box 1497 1 CLIA #: 33D2097541 Specimens: 1428 Madison Ave, Atran Bldg, Rm 2-25 T: 800-298-6470 New York, NY 10029 F: 212-241-0139 www.sema4.com 0 3 8 Mail: One Gustave L. Levy Place, Box 1497 2 CLIA #: 33D2097541 Specimens: 1428 Madison Ave, Atran Bldg, Rm 2-25 T: 800-298-6470 New York, NY 10029 F: 212-241-0139 www.sema4.com Mail: One Gustave L. Levy Place, Box 1497 3 CLIA #: 33D2097541 Specimens: 1428 Madison Ave, Atran Bldg, Rm 2-25 T: 800-298-6470 New York, NY 10029 F: 212-241-0139 www.sema4.com Mail: One Gustave L. Levy Place, Box 1497 4 CLIA #: 33D2097541 Specimens: 1428 Madison Ave, Atran Bldg, Rm 2-25 T: 800-298-6470 New York, NY 10029 F: 212-241-0139 www.sema4.com TABLE OF CONTENTS GENETIC TESTING FOR INHERITED CARDIOVASCULAR CONDITIONS 6 GENETICS AND INDICATIONS 6 TESTING METHODS, SENSITIVITY, AND LIMITATIONS 7 TURNAROUND TIME 9 SPECIMEN AND SHIPPING REQUIREMENTS 9 CUSTOMER SERVICES AND GENETIC COUNSELING 10 THE COMPREHENSIVE CARDIOMYOPATHY PANEL 11 DILATED CARDIOMYOPATHY (DCM) SUBPANEL 23 ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC) SUBPANEL 28 HYPERTROPHIC CARDIOMYOPATHY (HCM) SUBPANEL 30 LEFT VENTRICULAR NON-COMPACTION CARDIOMYOPATHY (LVNC) SUBPANEL 33 THE COMPREHENSIVE ARRHYTHMIAS PANEL 35 BRUGADA SYNDROME (BRS) SUBPANEL 40 CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) SUBPANEL 42 LONG / SHORT QT SYNDROME (LQTS / SQTS) SUBPANEL 44 AORTOPATHIES PANEL 46 CONGENITAL HEART DISEASE (CHD) PANEL 49 FAMILIAL HYPERCHOLESTEROLEMIA (FH) PANEL 52 PULMONARY HYPERTENSION (PAH) PANEL 54 METABOLIC CARDIOMYOPATHY PANEL 55 NOONAN SPECTRUM DISORDERS PANEL 57 HEREDITARY HEMORRHAGIC TELANGIECTASIA PANEL 59 REFERENCES 60 DISCLAIMER 69 Mail: One Gustave L.